The Bull Rankings scorecard — our quality-growth score is 27.9 / 100, built from three pillars scored 0–100: Quality 22, Growth 15, Value 65 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 16% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Sarepta’s current price of $18.95 sits on the cheap side of the biotech peer set, reflected in a Value score of 65. That alone should make the stock attractive, but the real driver is the company’s Quality pillar at 22, which our model interprets as a solid, defensible platform. The Growth pillar lags at 15, a reminder that the upside is limited by the present revenue trajectory. In the quarter ended 2026‑06‑30, revenue fell -20.4% YoY, and the firm posted a -6.9% profit margin and -8.9% ROE. Yet the market is pricing in a free‑cash‑flow growth of about 16% in year 1, tapering to 4% by year 10. That implied growth far exceeds the negative revenue trend, meaning the price already assumes a turnaround. If that turnaround materializes, the upside is significant; if not, the stock is over‑valued.
What the business actually is
Sarepta is a commercial‑stage biopharma that develops RNA‑targeted therapies for rare diseases. Its flagship products are exon‑skipping medicines for Duchenne muscular dystrophy: EXONDYS 51 (exon 51), VYONDYS 53 (exon 53), and AMONDYS 45 (exon 45). These drugs serve a niche patient population that requires a specific genetic mutation to be amenable to the therapy. The company also pursues a broader siRNA platform and gene‑therapy research, but the revenue engine today is dominated by the Duchenne line.
Why it can (or can't) keep compounding
The moat is the proprietary siRNA platform that enables precise exon skipping. Competitors would need to replicate the complex delivery system and secure the same mutation‑specific approvals, a process that can take a decade and billions of dollars. Sarepta’s free‑cash‑flow of $82 m in the trailing twelve months shows that the business is generating cash, albeit with a -6.9% margin that signals limited pricing power. The Debt‑to‑Equity of 0.7 indicates modest leverage, giving the company room to invest in R&D or acquisitions. The strongest model signal, Diluting shareholders, warns that the company may issue more shares to fund growth, which could erode per‑share value if the upside doesn’t materialize.
The valuation question
Using the P/S ratio of 1 and a market cap of $2.0 b, the price implies a sales multiple that is lower than many biotech peers, reinforcing the Value score. The reverse‑DCF tells us the market expects 16% FCF growth in year 1, declining to 4% by year 10. Compared to the -20.4% revenue decline, the implied growth is aggressive. If the company can reverse its revenue slide and lift margins, the price would be justified. Conversely, if revenue continues to fall, the valuation is already too high. The analyst consensus of $21.86 a year from now, with a range of $5–$38, reflects this uncertainty.
The bear case
The most damning figure is the -20.4% revenue growth YoY. A negative top line in a specialty‑drug company that relies on a narrow patient cohort is a red flag. If the market continues to shrink, the company’s ability to generate cash will falter, and the Diluting shareholders signal could materialize, further compressing value. The current -6.9% profit margin and -8.9% ROE suggest the business is not yet profitable, and the price assumes a turnaround that may not occur.
What would change our mind
- Revenue growth turning positive: If revenue growth turns positive, the implied growth would align more closely with the model’s 16% starting rate.
- Debt‑to‑Equity falling below 0.5: A stronger balance sheet would reduce dilution risk and improve the Quality pillar.